Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 5, 2022
Discovery & Translation
A gene therapy to drive hyperexcitable neurons back to baseline; plus a conditionally active IL-2 and more
BioCentury’s roundup of translational news
BioCentury | Jul 1, 2021
Distillery Therapeutics
Sensitizing TNBC to apoptosis-promoting BH3 mimetics with NamPRT inhibitors
DISEASE CATEGORY: Cancer
INDICATION: Breast cancer Inhibiting NamPRT, a nicotinamide adenine dinucleotide (NAD+) biosynthesis enzyme, could sensitize triple-negative breast cancer (TNBC) to BH3
INDICATION: Breast cancer Inhibiting NamPRT, a nicotinamide adenine dinucleotide (NAD+) biosynthesis enzyme, could sensitize triple-negative breast cancer (TNBC) to BH3
BioCentury | Sep 19, 2019
Distillery Therapeutics
Blocking the NAD+ biosynthesis enzyme NamPRT for PPM1D-mutant tumors
Items per page:
1 - 10 of 29